Search research articles
Contact Us
Filters
Showing results (291-300 of 464) with videos related to
Page
of 47
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 6, 2024
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease
Bruce E Sands, Julian Panés, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 12, 2019
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis
Bruce E Sands, Pam R Taub, Alessandro Armuzzi, et al.
Gut
|
March 19, 2013
Biosimilars in IBD: hope or expectation?
Krisztina B Gecse, Reena Khanna, Gijs R van den Brink, et al.
Biologicals : Journal of the International Association of Biological Standardization
|
October 23, 2012
Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012
Jonathan Kay, Brian G Feagan, Micheal S Guirguis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 19, 2008
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease
Jennifer Jones, Edward V Loftus, Remo Panaccione, et al.
Gastroenterology
|
October 14, 2008
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study
Brian G Feagan, Remo Panaccione, William J Sandborn, et al.
Gut
|
February 20, 2016
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis
|
June 5, 2024
Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn's Disease
Subrata Ghosh, Brian G Feagan, Rogério Serafim Parra, et al.
Intestinal Research
|
March 10, 2022
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, et al.
Journal of Crohn'S & Colitis
|
November 12, 2023
The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study
Bram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, et al.
Page
of 47
Search research articles
Search
Showing results (291-300 of 464) with videos related to
Sort By:
Page
of 47
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 6, 2024
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease
Bruce E Sands, Julian Panés, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 12, 2019
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis
Bruce E Sands, Pam R Taub, Alessandro Armuzzi, et al.
Gut
|
March 19, 2013
Biosimilars in IBD: hope or expectation?
Krisztina B Gecse, Reena Khanna, Gijs R van den Brink, et al.
Biologicals : Journal of the International Association of Biological Standardization
|
October 23, 2012
Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012
Jonathan Kay, Brian G Feagan, Micheal S Guirguis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 19, 2008
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease
Jennifer Jones, Edward V Loftus, Remo Panaccione, et al.
Gastroenterology
|
October 14, 2008
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study
Brian G Feagan, Remo Panaccione, William J Sandborn, et al.
Gut
|
February 20, 2016
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis
|
June 5, 2024
Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn's Disease
Subrata Ghosh, Brian G Feagan, Rogério Serafim Parra, et al.
Intestinal Research
|
March 10, 2022
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, et al.
Journal of Crohn'S & Colitis
|
November 12, 2023
The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study
Bram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, et al.
Page
of 47